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Background/objective: The Self Assessment of Treatment (SAT) questionnaire was developed to reflect key patient
reported outcomes of Neuropathic Pain (NP) treatments. This study aimed to understand how patients perceived
the relevance and ease of understanding of the questions in the SAT and to recommend modifications based on
patient and clinician interviews.
Methods: Semi-structured interviews were conducted with clinicians and NP patients to provide information
regarding treatment attributes and the impact of pain. Patients were debriefed on the SAT, a 5-item scale
evaluating pain, activity level, quality of life (QoL) and satisfaction with treatment (recommend treatment and
undergo treatment again). The SAT has a recall period reflecting back to the start of treatment. The qualitative
analysis software ATLAS.ti 5.0 was used to analyze patient transcripts. Changes to the SAT were integrated into the
questionnaire for a second round of debriefing interviews.
Results: Three NP clinicians and 44 patients (20 painful diabetic neuropathy, 16 HIV-associated neuropathy and 8
post herpetic neuralgia) with a mean age of 60.3 (12.3) years and an even gender distribution were interviewed.
Patient treatment experience included anticonvulsants (73%), antidepressants (34%), opioids (25%), and topical
medications (41%). Pain descriptors and treatment attributes were similar across the three NP groups. Pain relief
was judged the most important treatment attribute, followed by ability to undertake activities. Sleep improvement
was another important attribute. Activity limitations and QOL were perceived as too broad and non-specific, and
were split into 3 concepts each (activity limitations was split into self care, daily and physical activities and QOL was
split into sleep, emotions, and social function). A 7-day recall period was introduced. The item stem and response
options were made consistent, and a baseline and follow-up questionnaires were developed (except for the
satisfaction items) to enable monitoring onset of treatment benefit and change over time.
Conclusions: The content validity of the revised SAT was improved by the qualitative research, and NP treatment
benefits are reflected in a more consistent fashion by the changes. Baseline and follow-up versions make it possible
to perform assessments of change over time.
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Neuropathic pain (NP) is one of the most prevalent pain
etiologies [1]. It is a disorder of the peripheral nerves—the
motor, sensory and autonomic nerves that connect the
spinal cord to muscles, skin and internal organs [2,3], and
is a complex type of pain which requires a demonstrable
lesion as defined by the updated pain terminology and defi-
nitions provided by the International Association for the
Study of Pain (IASP); (http://www.iasp-pain.org/AM/Tem-
plate.cfm?Section=Pain_Definitions) [4]. Recently, Treede
and colleagues [5] redefined NP as “pain arising as a direct
consequence of a lesion or disease affecting the somatosen-
sory system.” Damage to the peripheral nervous system can
occur as a result of several disorders including diabetes,
infections such as herpes zoster (shingles) or HIV, trauma,
and autoimmune disorders [1,6]. While NP can occur in
any location, it often manifests in the extremities such as
the hands, feet, or legs. The overall prevalence of NP varies
from between 0.9 % to 8% in a general population [7,8].
Among HIV patients between 15% and 35% have NP, whilst
the prevalence is 15% in patients with painful diabetic neu-
ropathy or post herpetic neuralgia [9].
The NP symptom experience and the evolution of the
condition are highly idiosyncratic with individual expe-
riences varying widely between patients [1,6]. The course
of NP can be episodic and recurrent, slowly progressing
over many years, or it can quickly become severe and
debilitating. Both direct and indirect costs of NP to so-
ciety are substantial [10-14]. The consequences to the
individual patient profoundly impair emotional and
physical functioning with consequences such as move-
ment limitation, an inability to perform major activities
of daily living, needing help for personal care, frequent
use of health care services, and work productivity losses
[10,11,15,16]. The disease burden is also substantial as
shown in a comparison of the world wide burden to
patients of suffering from NP assessed in a cross na-
tional study [17]. The intensity of the pain as well as the
duration of the pain contributes to the distress asso-
ciated with NP.
Important outcome domains were identified in a sur-
vey of people with pain conducted by the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) [18]. These domains formed the
basis of the IMMPACT group’s recommendations on a
core set of outcome domains to be included in eva-
luation of treatment benefits [19]. Whilst pain relief
measures are used to determine whether the patient has
actually benefited from an intervention, and provide
valuable information on how effectively pain is being
managed, patient satisfaction measures capture the per-
sonal evaluation of the intervention provided [20].
Despite newer treatment modalities NP remains difficult
to treat. Treatment of NP in the past mainly consisted ofregular analgesics, suggesting patients are receiving sub-
optimal treatment options [21]. However, recently, the
European Medicines Agency [22] and the US Food and
Drug Administration [23] approved the use of a high-
concentration capsaicin topical patch 8% (QUTENZA™).
Capsaicin, in high concentrations like the QUTENZA™
patch, is a transient receptor potential vanilloid 1 (TRPV1)
agonist that is useful in relieving pain. Whilst the
QUTENZA™ EU label covers the treatment of peripheral
NP in non-diabetic adults, either alone or in combination
with other medicinal products for pain, the US label is
licensed for the management of neuropathic pain asso-
ciated with post herpetic neuralgia [22,23].
The five-item Self Assessment of Treatment (SAT)
questionnaire was developed internally by Neurogesx for
use in clinical trials to measure key areas of treatment
benefit (i.e. pain, activities, quality of life and treatment
satisfaction) recommended by IMMPACT [18]. Since
psychometric documentation of the SAT was lacking, a
post hoc analysis was conducted using trials data to
validate the SAT [24]. The results indicated that the three
pain and impact items were reliable and valid, whilst the
satisfaction items performed less well [24]. The SAT has
been used as a secondary end-point in two trials assessing
treatment with Capsaicin in human immunodeficiency
virus (HIV)-associated peripheral neuropathy (HIV-PN)
with beneficial results for QUTENZA™ cited in the me-
dical review conducted by the FDA [25], as well as by [26]
for the treatment of post herpetic neuralgia [22].
The psychometric performance suggested that the
SAT items could be further improved with additional
patient input to ensure that items are clearly phrased,
relevant and comprehensive, easy to understand, and
that the response options and recall period are adequate
to better assess pain related treatment benefits when
used in clinical trials. Therefore, the purpose of this
study was to better understand how well the SAT ques-
tionnaire reflects what patients perceived as relevant
aspects of pain treatment and to document patient
understanding of the individual SAT questions. Addi-
tionally, recommendations were provided on how to
modify the instrument to be better suited to assess the
benefits of pain treatment by changing the recall period,




Clinicians were interviewed to derive information from
the clinical perspective on the most relevant neuropathic
pain symptoms as well as the benefits and drawbacks of
neuropathic pain treatments. A total of 3 clinicians with
expertise in pain therapy, anesthesia intensive care, neu-
rology and endocrinology participated in one-on-one
Wiklund et al. Health and Quality of Life Outcomes 2013, 11:8 Page 3 of 13
http://www.hqlo.com/content/11/1/8telephone interviews. On average, the experts reported
seeing 20 patients per week with NP. This consultation/
interview was conducted up-front to ensure that patient
interview questions would be appropriately addressed in
the semi-structured interview guide.
Patient interviews
General inclusion criteria applied to all study partici-
pants were as follows: male or female; 18 years of age or
older; presence of painful diabetic peripheral neuropathy
(PDPN) or NP due to either post herpetic neuralgia
(PHN) or painful HIV associated neuropathy (HIV-AN);
presence of painful symptoms due to neuropathic pain
with a numerical pain rating score (NPRS) of ≥4 at the
time of screening; on a stable (not as needed, i.e., PRN)
treatment for neuropathic pain for at least the past 3
months prior to screening; able to participate in a 90-
minute, in-person interview; fluent in English (able to
read and write); and willing and able to complete
informed consent prior to study entry. Specific inclusion
criteria for each pain group were as follows: PDPN, a
diagnosis of painful, distal, symmetrical, sensorimotor
polyneuropathy that is due to diabetes and made by the
primary treating physician or Investigator at least one
year prior to the screening visit; PHN, a diagnosis of
PHN made by the primary treating physician or Investi-
gator with at least 6 months of pain since shingles
vesicle crusting; and HIV-AN, prior medical history of
HIV-1 infection and prior diagnosis of HIV-DSP or anti-
retroviral toxic neuropathy documented by the consult-
ing neurologist or investigator.
Exclusion criteria applied to all participants were as
follows: parenteral opioid medication use; active sub-
stance abuse or history of chronic substance abuse
within the past year, or prior chronic substance abuse
(including alcoholism); neuropathic pain areas located
only on the face, above the hairline of the scalp, and/or
in proximity to mucous membranes; significant pain of
an etiology other than one type of neuropathic pain
(PHN, PDPN, or HIV-AN); significant ongoing pain
from other cause(s) that may interfere with judging
neuropathic pain, any implanted medical device (spinal
cord stimulator, intrathecal pump, or peripheral nerve
stimulator) for the treatment of neuropathic pain; recent
history of a significant medical-surgical intervention; a
clinically-relevant medical or psychiatric condition which,
in the opinion of the investigator and/or coordinator,
would interfere with completing the study including but
not limited to sensory problems, cognitive impairment,
acute mental illness, or inadequately treated depression or
anxiety.
Because the SAT was developed for use in trials assessing
the efficacy of the QUTENZA™ patch, efforts were taken
to recruit a subset of patients who had experience withQUTENZA™ treatment. Similarly, efforts to recruit
patients from the USA with a variety of socio-demographic
backgrounds, as well as varied disease and treatment
experiences, were implemented to ensure a diverse popula-
tion was involved. Protocols were approved by an institu-
tional review board, and patient consent was obtained
prior to discussion of study related materials. Clinicians
completed an enrollment and clinical form documenting
each participant’s eligibility and treatment history.
During the semi-structured one-on-one qualitative
interviews, participants were asked to describe their ex-
perience with NP, their treatment history, and how and
why they value available treatment options. Interviews
included questions and exercises designed to elicit par-
ticipant discussion of salient pain treatment attributes
and levels. Participants were asked to rate the import-
ance of treatment attributes on a scale from 0 (Not Im-
portant) to 5 (Very Important). All interviews were led
by a trained moderator. The interview guide included
both structured and open-ended question.
During the interviews, patients were asked to complete
the SAT and were then debriefed on each of the ques-
tions to uncover any issues with the SAT questions. The
SAT was revised after the first round of interviews and
additional debriefing interviews were conducted to en-
sure all changes were perceived as relevant improve-
ments to the SAT.
Measures
During the qualitative interview, in addition to the
SAT, participants completed a NPRS, and a brief socio-
demographic questionnaire with questions regarding
age, gender, ethnicity, employment, education, and co-
morbid conditions.
Self Assessment of Treatment (SAT) questionnaire
The SAT evaluation form included 3 questions with 5-
point response options to assess the impact of treatment
on three areas (pain relief; activity level; and quality of
life), and 2 additional items regarding: 1) whether the
patient would undergo the treatment again, and 2) a
comparison of the study treatment to previous treat-
ments for pain. For each question, the subject checked a
box on a 5-point scale, where the middle option (0) indi-
cated a neutral response and the lower (−2) and higher
(+2) options indicated a negative or positive response,
respectively. For example, SAT Item 1 asked the patient
“How do you assess your pain relief after treatment in
this study?” with the response options of “I feel my pain
is much worse” (−2), “somewhat worse” (−1), “no better
and no worse” (0), “somewhat better” (1), and “much
better” (2); Question 2 “How do you assess your activity
level after treatment?” with responses ranging from I feel
much less active (−2), I feel somewhat less active (−1), I
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more active (1) to I feel much more active (−2); Ques-
tion 3 “How has your quality of life changed after treat-
ment?” I feel my quality of life is much worse (−2), I feel
my quality of life is somewhat worse (−1), I feel my qua-
lity of life is no better and no worse (0), I feel my quality
of life is somewhat better (1), I feel my quality of life is
much better (2); Question 4 “Would you undergo this
treatment again?” was “administered to subjects with
only three response options: “No, absolutely not” (−2),
“Unsure” (0), and “Yes, definitely” (2) and Question 5
“How do you compare the treatment in this study to
previous medication or therapies for your pain?” The
item performance and psychometric properties of the
SAT have recently been examined [24].
The Numerical Pain Rating Scale (NPRS)
The NPRS is commonly used in pain medication trials
[27] and is one of the many pain items in the modi-
fied Brief Pain Inventory (BPI) [28,29]. The NPRS is
an 11-point graded scale ranging from 0–10 with 0
depicting “no pain at all” and 10 denoting “worst pain
imaginable.”
Data analysis
Descriptive statistics (mean, standard deviation and fre-
quency) were used to characterize the interview sample
in terms of sociodemographic data, health status, the
numerical pain rating and clinical characteristics. All
interviews were audio recorded with the participant’s
permission and transcribed for analysis. The qualitative
analysis was conducted by coding the transcripts using
ATLAS.ti version 5.0 [30] software to organize the coded
concepts using a coding dictionary developed by the
coding staff as the coding process continued and con-
cepts were identified. This process was adhered to sys-
tematically analyze, code, and compare quotes from
participant interviews in order to evaluate the underlying
structure of the qualitative data.
The information gained in the interviews was used to
explore any potential relevant missing items and to pro-
vide recommendations on how to modify the SAT for
use in future studies.
Results
Clinical expert input on neuropathic pain
According to the clinical experts, there is a high degree
of variability in descriptions of NP experiences among
patients with the same type of NP but the descriptions
do not differ significantly across types of NP. Experts
indicated that patients often report challenges with pain
relief and there is a low efficacy rate with the existing NP
treatments. Common oral medications prescribed for NP,
such as anticonvulsants, opioids, and antidepressantsprovide continuing efficacy but the dose titration process
can be time consuming and many patients experience side
effects from oral medications. In contrast, topical medica-
tions offer a more agreeable side effect profile but the du-
ration of efficacy is limited in comparison with the oral
medications. Interestingly, the experts suggested that the
QUTENZA™ patch may offer an extended duration of
efficacy compared to other topical treatments for NP and
it may be particularly beneficial for patients experiencing
burning superficial pain with allodynia such as those with
PHN or HIV-AN. Expert opinion also included some
negative aspects of QUTENZATM such as painful applica-
tion, or a lengthy application process requiring assistance
from a medical professional.
Patient demography and clinical characteristics
A total of 44 patients participated in the one-on-one
qualitative interviews in California, Florida, Georgia, and
Virginia over a 3-month period. Twenty patients suf-
fered from PDPN, 16 had HIV-AN and eight had PHN.
Demographic and clinical characteristics of the partici-
pants are provided in Table 1 and Table 2, respectively.
Patient experiences with neuropathic pain
Participants reported experiencing many different types
of pain and pain symptoms. The most prevalent pain
descriptions included: burning, mentioned by 30%
(n=13) of the participants, numb (n=12. 27%), sharp
(n=10, 23%), pins and needles (n=9, 21%) and throbbing
pain n=6, (14%). Less frequent pain descriptors charac-
terized the pain as hot, stabbing, tingling, aching, dull,
heavy, and shooting pain, whilst only one or two partici-
pants described the pain as cramping, electrical shock,
freezing/cold, hypersensitive, biting, clamping, cutting,
piercing, pinching, pressure, and tight. There was no
major difference between the NP populations in the way
they described their pain (Table 3).
These pain symptoms had an impact on daily activities
(Table 4) and aspects of participants’ personal lives. The
most common impact of NP on daily activities reported
by participants across all pain groups was that pain
affected the ability to “do” or engage in daily activities,
which was reported by 61% (n=27) of the participants
with no difference across NP populations. Participants
commonly reported that neuropathic pain interrupted
daily activities and that they avoid doing certain acti-
vities as a result of their neuropathic pain.
Participants were asked to provide examples of the ac-
tivities affected by neuropathic pain (Table 4). Specific
daily activities that were adversely affected by neuro-
pathic pain included: shopping, work, cooking, driving
or transportation, cleaning, and wearing clothing. Daily
activities identified by 1 or 2 participants included: ca-
ring for someone else, going to appointments, home
Table 1 Demographic characteristics and self report Co
Morbid conditions
Total N=44
Mean Age, Years (SD) [Range] 60.3 (12.3) [30.0-80.0]
Gender (n, %)
Female 23 (52.3%)
Male 21 (47.8 %)
Ethnicity (n, %)
Not Hispanic or Latino 38 (90.5%)
Hispanic or Latino 4 (9.5%)
Race (n, %)1
White 31 (70.5%)
Black or African American 10 (22.7%)
Other2 3 (6.8%)






Homemaker 1 (2.3 %)
Other3 1 (2.3%)





















1Participants were permitted to select more than one response.
2 Other racial backgrounds reported by participants included: European Mix
(n=1); Mestizo (n=1).
3 Other employment reported by participants included: Not specified (n=1).
4 Other health conditions reported by participants included: AIDS (n=2); CHF,
Adema, Neuropathy, Right Shoulder Torn (n=1); Emphysema (n=1); Heart
attacks (n=1); Heart Disease (CAD), RLS (n=1); High cholesterol, indigestion
(n=1); HIV (n=1); HIV, Gout (n=1); Migraines (n=1); Neuropathy (n=1).
Table 2 Clinical characteristics
Total N = 44
Mean of Patients’ Onset of Neuropathic Pain
Diagnosis in Years (SD) [Range]
7.5 (8.1) [1.0-40.0]
Type of Neuropathic Pain (n, %)
Postherpetic Neuralgia (PHN) 8 (18.2%)
HIV-associated Neuropathy (HIV-AN) 16 (36.4%)
Painful Diabetic Peripheral Neuropathy (PDPN) 20 (45.5%)
Mean of Patient’s Rating of Pain (SD) [Range] 6.9 (1.7) [3.0-10.0]













Mean Patient Height, feet (SD) [Range] 5.5 (0.4) [4.5-6.2]
Mean Patient Weight, pounds (SD) [Range] 196.7 (45.9)
[108.0-315.0]
1These categories are not mutually exclusive.
2Other Opioid medications reported by participants included: Darvocet (n=1);
MS Contin (n=1); Tramadol (n=6); Vicodin (n=1).
3Other Non-Opioid medications reported included: Advil (n=2); Aleve (n=1);
Amitriptyline (n=3); Aspirin (n=2); Baclofen (n=1); Carbamalbpine (n=1);
Celebrex (n=1); Cymbalta (n=1); Diclofenac (n=1); Glipizide (n=1); Motrin (n=1);
Naproxen (n=2); Nortriptyline (n=1); Topamax (n=3); Tylenol (n=1); Tylenol
Extra Strength (n=2).
4Other Topical medications reported by participants included: Amitriptyline
5%, Gabapentin 5%, Ketamine 8% (n=1); Zotrix 0.75 Cream (n=1).
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of neuropathic pain on daily activities was similar across
pain types. During these discussions, sleep disturbance
was commonly identified and had a negative impact
among 20 participants (46%) across pain types.
The physical activities affected by neuropathic pain
varied by NP population type. Forty five percent of parti-
cipants with PDPN (n=9) and 56% of participants with
HIV-AN (n=9) identified walking and 10% (n=2) and
19% (n=3) respectively identified standing, as physical
activities commonly affected by NP, while none of the
participants with PHN reported difficulty with these ac-
tivities (Table 4). Gardening and yard work were report-
edly affected by PHN (25% of participants, n=2) and
PDPN (10% of participants, n=2) but not at all by HIV-
AN participants. Exercise was only discussed as an
affected physical activity by HIV-AN participants (n=5,
Table 3 Pain descriptions
Pain
description
Illustrative quotation PHN PDPN HIV-AN All
(n=8) (n=20) (n=16) (N=44)
Burning
02-102-1-0: It's always like burning, I don't know
how else to say, but it feels like even clothes touching,
it's burning. Apparently it's not, but that's what it feels like.
4 7 2 13
(50%) (35%) (12%) (30%)
04-105-1-0: When it gets really bad and it will burn. Feel
like its hot burning.
Numb
05-102-3-0: It’s a tingling ah in your feet and it goes up to
your um ankle and then it’s like numbness like you don’t feel
nothing. You can be walking with flip-flaps and the next day you
know you think you still have your shoes on, and you’re walking
out in your bare feet.
0 8 4 12
(0%) (40%) (25%) (27%)
Sharp
01-102-2-0: It just comes on, I mean it’s like a sharp pain and
then it just-I usually just try to walk it off or rub it off and then
it goes away-and then it returns.
1 3 6 10
(13%) (15%) (38%) (23%)
03-106-2-0: Uh, [clearing throat] it's-it's like when it's very severe
it's like I'm-I'm walking on a bed of nails or thumb tacks and
it, uh, just tingling and very, very, uh, very painful, sharp, sharp pain.
Pins and Needles
01-101-2-0: Not so much pain as it was pins and needles
and little stabbing and numbness.
1 6 2 9
(13%) (30%) (13%) (21%)
03-103-2-0: A pinprick--you know, lots of pins, poking pins
kind of a feeling kind of thing, so it's hard pain to describe,
but that's as close as I can get.
Throbbing
08-104-3-1: I think the fact that it's when it starts it is-it will
kind of throb and throb and throb for a while.
0 2 4 6
(0%) (10%) (25%) (14%)
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HIV-AN n=3, 19%) and sitting (PHN n=2, 25%; PDPN
n=1, 5.0%; HIV-AN n=3, 19%) were affected for partici-
pants in all pain groups, with 23% (n=10) of the partici-
pants identifying playing sports as a problem and 14%
(n=6) of the participants identifying sitting as a problem.
Other physical activities, mentioned by only 1 or 2 parti-
cipants, included lifting and playing with kids. Partici-
pants in all pain groups reported an impact on social
activities, but this impact was reported less frequently by
participants with HIV-AN than by participants with
PHN or PDPN.
In addition to the impact on activities, participants dis-
cussed the impacts of NP on their personal lives. About
27% (n=12) of participants across all pain groups noted a
negative impact of NP on relationships quoting expe-
riences such as “if you go somewhere with a friend or
something and then you have to be-I’ll be like sitting there
and then have the sharp pains and then they’re like oh, my
gosh, what’s wrong with you? You know, it does interfere
with your relationships.” Similarly, about 25% (n=11) of
participants mentioned that pain had a negative effect on
their emotional well-being. Only one or two participants
reported experiencing changes in mental state, outlook on
life, sex life, feeling short tempered and difficulty concen-
trating/focusing as a result of neuropathic pain.
Although descriptions of pain experiences and impacts
were highly variable, the experiences reported by patientswere not different across the NP populations. This similar-
ity across pain types is consistent with the observations of
high intra-pain type variability reported during clinician
interviews.
Treatment experiences
Patients were asked to discuss their experience with NP
treatments. The most commonly reported type of treat-
ment was anticonvulsant medication followed by antide-
pressants (Table 5). Participants also reported treatment
with opioid and non-opioid analgesics such as NSAIDs
and acetaminophen. Experiences with pain treatments
other than oral medications included topical treatments
(excluding QUTENZA™). Experience with topical treat-
ments and the QUTENZA™ patch were more common
among participants with PHN (n=5, 63% and n=2, 25%)
whilst in HIV-AN 44% (n=7) used the QUTENZA™
patch in contrast to only 10% (n=2) and 5% (n=1) in
PDPN patients. Physical therapy, acupuncture and injec-
tions were treatment options only reported by single in-
dividual patients.
During the discussion of current and prior treatments,
participants were specifically asked to share their expe-
riences with treatment use, availability, cost, and side
effects. It is important to note that some participants
have tried several different medications within a treat-
ment type and reported different experiences for the dif-
ferent medications.
Table 4 Impact of neuropathic pain
Impact on daily
activities Illustrative quotation
PHN PDPN HIV-AN All
(n=8) (n=20) (n=16) (N=44)
Affects ability to do activities 01-104-2-0: I mean it-it-it’s bad. It hurts, uh, so bad that, you
know, sometimes I can’t get up. I can’t walk.. . . You can’t do
anything. And, you know, you do whatever and you just sit
there and do nothing.
4 12 11 27
(50%) (60%) (69%) (61%)
03-102-2-0: When I-when I go into, um-when I-when my
pain starts, yeah, absolutely, I can't do anything. I can't think.
05-104-30: Um, because I can't really do the things that
I really want to do.
05-105-3-0: Well, be-it bothers me because I can't get this
stuff done I need to get done. . .And I couldn't cook for the
children, I didn't go to the grocery store, so there's nothing
really there for them to make when I'm not able to fix them
something their selves. So that really bothers me because
then I really got to get
up and, uh, it really hurts. You know what I'm saying,
I got to get up.
Interrupts Activities 01-102-2-0: If I’m trying to do something and it comes on,
it interrupts what I’m doing and then, of course, I have to
stop and wait ‘til it quits hurting and then continue with
whatever I was doing. So, consequently, I don’t do near all
the things that I used to do.
2 5 1 8
(25%) (25%) (6%) (18%)
02-101-1-0: It really doesn't affect anything, I just have to stop
certain things after a certain time.
04-104-2-0: Well, it stops me from doing a lot of, uh, walking
and doing things that I'm doing, I have to stop.
Avoid doing activities 03-103-2-0: I try not to walk much, I always try to find a way
to sit down where it's best to put my feet up.
1 4 2 7
(13%) (20%) (13%) (16%)
06-101-2-1: Well, if-if I'm going any place, you know, that I have
to do any walking or-I tend not to-to go if I can help it, you know.
08-101-3-1: Well, socially and personally, it goes back to do-being
able to do the little things that-uh, that causes me to be afraid.
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use each treatment, most participants (n=75, 82%)
described treatments as easy to use. Anticonvulsant medi-
cations were generally reported as easy to use by between
73%–88% of participants across all pain groups, as were
opioids (65–100%) and non-opioid analgesics (57%–









Total 95 32 15
N=44 (73%) (34%)
PHN 23 5 3
N=8 (63%) (38%)
PDPN 42 16 9
N=20 (80%) (45%)
HIV-AN 30 11 3
N=16 (69%) (19%)
1One PDPN participant was previous treated with Qutenza but did not recall the tre
experience.using topical treatments indicated that the treatments
were easy to use. Half (n=5) of the participants that had
tried the QUTENZATM patch said that it was easy to use.
During the discussion of treatment use, participants spe-
cified both positive and negative aspects of treatment that
influenced their opinions on treatment usability. Pain








11 14 8 10
(25%) (32%) (18%) (23%)
4 1 5 2
(50%) (13%) (63%) (25%)
5 7 2 11
(25%) (35%) (10%) (5%)
3 6 1 7
(19%) (38%) (6%) (44%)
atment. Therefore, this participant was not asked about the treatment
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pants. Other participants mentioned duration of relief, im-
provement in sleep, ability to take the treatment with
other medications, onset of relief, cost, and side effects.
Twelve out of 16 participants (75%) with HIV-AN
reported that pain relief was important in their assessment
of treatment usability. There were few problems associated
with oral medications although 4 participants (13%) com-
mented on the high pill burden associated with anticon-
vulsants. More than half of the participants (n=25, 57.7%)
reported changing neuropathic pain treatments at least
once during the course of their treatment experience. The
main reasons for switching were ineffective treatments
(n=13, 50%) and side effects (n=11, 42.3%). Other reasons
for discontinuing a previous therapy included: physician’s
decision, insufficient pain relief, contraindication with
another medication, high cost, high pill burden, too much
trouble to use, short duration of effectiveness, medication
taken off the market, messy application, and loss of effect-
iveness. The most common reason for starting a new
medication was to provide additional pain relief (n=6,
23%). Participants also indicated that new mediations were
added to on-going treatments to help with sleeping, break
through pain, or severe pain.
In the rating of treatment attributes, pain relief (identi-
fied by 47% of the participants, n=45) was identified as
the key aspect of treatment. By treatment, pain relief
was named as the best aspect of treatment with the
highest frequency for opioids (n=4, 64%), QUTENZA™
(n=4, 60%), and anticonvulsants (n=11, 50%). Other
characteristics identified as “best aspects of treatment”
included ease of use, no side effects, availability, cost,
help with sleeping, duration of effectiveness, and quick
on-set. “Reduction in pain” was rated as the most im-
portant attribute across all pain groups with an average
score for all of = 4.7 (range 0–5). Among PHN patients
the average was 5.0, PDPN4.6, and HIV-AN=4.8. Partici-
pants with PHN and HIV-AN rated ‘Duration of pain re-
lief ’ as tied with ‘reduction in pain’ as the two most
important attributes in determining treatment success
(average scores of 5.0 out of 5 and 4.8, respectively). The
second highest rated attribute for participants with
PDPN was “improvement in ability to do your usual ac-
tivities” (average score = 4.5).
The most common treatment characteristic, irrespect-
ive of mode of administration, identified by participants
as the “worst aspect of treatment” was side effects (28%).
Pill burden was identified as the worst aspect for nine
oral therapies discussed by participants.
Both clinicians and patients commented on topical as
opposed oral medications with topical medication offering
a more favorable side effect profile. These finding suggest
that side effects play an important role when it comes to
treatment satisfaction and its evaluation in clinical trials.Factors for treatment success
Characteristics of ideal treatments could be separated
into 3 categories: results of treatment (n=40), route of
administration (n=33), and treatment use (n=19). Ideal
treatment attributes described by participants were ge-
nerally similar across pain groups and focused on
complete elimination of pain, permanent pain relief and
no side effects. As to most favored routes of administra-
tion, taking a pill, use of a patch, and topical administra-
tion were reported in that order.Patient feedback on the SAT
During the debriefing interviews, several issues were
reported related to the SAT. In question 1, the question
stem and the response options presented challenges
since they were not consistent, e.g., the question asks for
an assessment of the pain level and the response option
states the pain is worse/better after treatment. Question
2 asks respondents to assess the activity level after treat-
ment. Participants found “activity level” to be too broad
and unspecific and provided specific examples on acti-
vities affected by pain. Question 3 asks about changes in
quality of life after treatment which generally was con-
sidered to be an unspecific concept. Similar to the ques-
tion on activity levels, patients reported items they
found were important to their quality of life. In question
4 where respondents are asked to state if they would like
to undergo treatment again it became obvious that the
response options did not fit the questions stem and were
not consistent with responses to the questions. Question
5 asks respondents to compare the treatment to other
pain treatments with responses describing level of pre-
ference for previous or current treatment. Hence the
question stem and the response options did not match
which caused problems for the respondents.
Additionally, the recall period for all items is retrospect-
ive requiring patients to reflect back to when treatment
was started which is difficult to remember precisely and
therefore fraught with recall bias. The use of positive and
negative numbers to depict the response options, espe-
cially the negative numbers also caused confusion.Modifications of the SAT
The patient input suggested that items 2 (activity level)
and 3 (quality of life) were too broad and nonspecific.
Therefore, these questions were split into 3 sub-questions
each using the detailed information derived in the qualita-
tive research. The questions were revised to include exam-
ples of specific activities to describe examples of self care
activities, daily activities and physical activities, all fre-
quently mentioned in the interviews. With regards to
question 3, the same procedure was followed replacing
quality of life with specific aspects of your life using
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tive examples, these again were derived from the
interviews.
Questions 4 and 5 they were rephrased to “Based on
your experience with the study treatment, would you
like to receive this treatment again?” (no, definitely not–
yes, definitely) and “Based on your experience with the
study treatment, overall how does this treatment com-
pare to other treatments you have received in the past?”
(very much worse–very much better). The recommenda-
tion is to use questions 1–3 at baseline and predefined
follow up visits, and to include questions 4 and 5 at the
final visit only.
For questions 1–3, the recall period was changed to
“Over the past 7 days.” The response options for ques-
tions 1–3 were changed to not at all/slightly better/
moderately better/quite a bit better/very much better
for all 3 questions to improve consistency.
Baseline and follow up versions of SAT questions 1–3
were also developed to enable assessment of response to
treatment over time. Given the nature of questions 4 and
5 no baseline questions were developed for these items.
The changes made to the SAT to address the issues
identified during patient interviews are summarized in
Table 6.
Discussion
There are a couple of pain satisfaction surveys. The
American Pain Society (APS) Satisfaction Survey is one
of these and has shown that satisfaction was influenced
largely by effectiveness of medication, independent of
pain intensity [31]. This suggests that a satisfaction sur-
vey related to the effectiveness of a pain medication is
an important measurement tool for use in clinical trials
of novel pain treatments which is also consistent with
the recommendations of the IMMACT group [18].
Even though the APS Satisfaction Survey focused on
pain management in general practice, it was not directly
related to satisfaction with medication. The same applies
to another pain survey, the Pain Treatment Satisfaction
Scale (PTSS) [32] which measured satisfaction in patients
receiving treatment for acute or chronic pain; it was not
designed for use in clinical trials, as it evaluates satisfac-
tion with medical care received as well as pain medication.
Although a variety of instruments capturing patient satis-
faction exists, none of these measures were identified as
appropriate for assessing patient satisfaction with medica-
tion used to evaluate the effect of treatment of chronic
pain in the context of a clinical trial, which led to the
development of the SAT.
In all, forty-four patients across three NP populations
were interviewed which can be regarded as a sufficiently
large sample size. The consistency of the findings sup-
port content validity and concept saturation as definedby Leidy and Vernon [33]and Magasi et al. [34]. Specific-
ally, they define saturation as the point at which no sub-
stantially new information/concepts continue to emerge
beyond what has been previously mentioned when inter-
viewing the last few patients. Additional support can be
found in the FDA guidance document [35], “The num-
ber of patients is not as critical as interview quality and
patient diversity included in the sample in relation to
intended clinical trial population characteristics.” In ge-
neral, the 3 NP populations were similar in the way they
described pain and the impact of pain symptoms. Clini-
cians reported a high variability in terms of pain report-
ing across patients but not across different NP types.
Although a small number of clinicians were interviewed
for this study, they provided similar input on the va-
riability of pain experiences. The pain descriptors used
by patients also varied, but were consistent irrespective
of NP type and very also similar to the descriptors
included in the McGill short form pain questionnaire
where pain is referred to as debilitating, burning, sharp,
jabbing, deep, and aching, and can persist for months or
years [36,37]. The similarity in pain description across
all three NP types indicates that the content of the SAT
is applicable for use across the different NP populations.
Similarities supporting the use of the SAT across all
three NP populations prove that the concept of satisfac-
tion with treatment assessment is fundamental in the
evaluation of pain medication with both the clinical
experts and the patients rating the reduction in pain as
the most important treatment attribute followed by the
ability to perform usual activities (by the PDPN popula-
tion) and duration of pain relief (by the PHN and HIV-
AN populations).
As pain reduction is unanimously identified as the
most important aspect of treatment, it is not surprising
that changes in pain have been shown to be closely
linked to improvement in quality of life [13]. Once again,
in the interviews, no difference was seen between the
groups in terms of the impact of NP and the disruption
of ability to perform daily activities and its impact on
quality of life. With similarities in terms of pain defini-
tions and similarities in the way that it affects individuals
across all NP types as well as the fact that pain reduction
is a critical component of treatment, it appears that the
SAT would be appropriate for use in all NP types.
Pain is one area of research where the subjective ex-
perience and reporting by the patient is well-established
and the concept of self assessment is particularly rele-
vant. The importance of patient report/self assessment
can be seen in work conducted by Taylor-Stokes and
colleagues [38] where there was significant association
between patient- and physician- rated severity but phy-
sician and patient ratings were discordant with physi-
cians underestimating severity in 46.7% of patients who
Table 6 Summary of suggested revisions to the SAT
Item Original Changes Revised baseline item Revised follow up and last visit items
Instructions Please mark one response for
each question
Instructions to mark responses
clarified.
Instructions: Please mark your response by marking
one of the boxes for each question below.
Instructions: Please mark your response by marking
one of the boxes for each question below.
Item 1 How do you assess your pain
level after treatment in this
study?
1. Item developed to assess pain level
at baseline
1. Over the past 7 days, how would you rate your pain
level?
1. Over the past 7 days, how much has the study
treatment improved your pain level?
- I feel my pain is much worse
(−2)
2. Recall period changed to 7 days - No pain at all - Not at all
- I feel my pain is somewhat
worse (−1)
3. The response options were made
consistent with the item stem and
with other response options on the
questionnaire
- Mild pain - Slightly better
- I feel my pain is no better
and no worse (0)
4. Weighting numbers were removed - Moderate pain - Moderately better
- I feel my pain is somewhat
better (1)
- Severe pain - Quite a bit better
- I feel my pain is much better
(2)
- Very severe pain - Very much better
Item 2 How do you assess your
activity level after treatment in
this study?
1. Item developed to assess activity at
baseline.
2. Over the past 7 days, how much has pain affected
your ability to do the following activities:
2. Over the past 7 days, how has the study treatment
improved your ability to do the following activities:
- I feel much less active (−2) 2. Recall period changed to 7 days A. Daily self care activities, such as showering and
dressing?
A. Daily self care activities, such as showering and
dressing?
- I feel somewhat less active
(−1)
3. The item was split into several
questions that are more targeted to
pain relief aspects noted during the
qualitative interviews
B. Daily activities, such as cleaning, fixing things
around the house, grocery shopping, preparing meals,
going to appointments, caring for someone else and
other day to day tasks?
B. Daily activities, such as cleaning, fixing things
around the house, grocery shopping, preparing meals,
going to appointments, caring for someone else and
other day to day tasks?
- I feel no more and not less
active (0)
4. The response options were made
consistent with the item stem and
with other response options on the
questionnaire
C. Physical activities, such as walking, exercising,
gardening or yard work?
C. Physical activities, such as walking, exercising,
gardening or yard work?
- I feel somewhat more active
(1)
5. Weighting numbers were removed Response options for A, B, and C Response options for A, B, and C
- I feel much more active (−2) - Not at all - Not at all
- Slightly - Slightly better
- Moderately - Moderately better
- Quite a bit - Quite a bit better
- Very much= - Very much better
Item 3 How has your quality of life
changed after treatment in
this study?
1. Item developed to assess quality of
life at baseline.
3. Over the past 7 days, how much has pain affected
the following aspects of your life:
3. Over the past 7 days, how much has the study
























Table 6 Summary of suggested revisions to the SAT (Continued)
- I feel my quality of life is
much worse (−2)
2. Recall period changed to 7 days A. Emotional wellbeing such as mood, temperament
or outlook on life?
A. Emotional wellbeing such as mood, temperament
or outlook on life
- I feel my quality of life is
somewhat worse (−1)
3. The item was split into several
questions that are more targeted to
QOL aspects noted during the
qualitative interviews
B. Ability to sleep? B. Ability to sleep?
- I feel my quality of life is no
better and no worse (0)
4. The response options were made
consistent with the item stem and
with other response options on the
questionnaire
C. Social functioning, such as participating in activities
or relationships with friends and family?
C. Social functioning, such as participating in activities
or relationships with friends and family?
- I feel my quality of life is
somewhat better (1)
5. Weighting numbers were removed Response options for A, B, and C Response options for A, B, and C
- I feel my quality of life is
much better (2)
- Not at all - Not at all
- Slightly - Slightly better
- Moderately - Moderately better
- Quite a bit - Quite a bit better
- Very much - Very much better
Item 4 Would you undergo this
treatment again?
1. This item now does not ask if the
participant “would undergo”
[treatment] as in the original question
4. Based on your experience with the study treatment,
would you like to receive this treatment again?
- No, definitely not (−2) 2. Weighting numbers were removed - No, definitely not
- No, probably not (−1) - No, probably not
- Unsure (0) - Unsure
- Yes, probably (1) - Yes, probably
- Yes, definitely (2) - Yes, definitely
Item 5 How do you compare the
treatment in this study to
previous medication or
therapies for your pain?
1. The item was rephrased to clarify
the intended meaning of the question
5. Based on your experience with the study treatment,
overall, how does this treatment compare to other
treatments you have received for your pain?
- Very much prefer previous
(−2)
2. The response options were revised
to fit the item stem.
- Very much worse
- Somewhat prefer previous
(−1)
3. Weighting numbers were removed - Somewhat worse
- No preference (0) - No better no worse
- Somewhat prefer this
treatment (1)
- Somewhat better
- Very much prefer this
treatment (2)
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http://www.hqlo.com/content/11/1/8reported severe PDPN. Therefore, a patient-reported tool
is critical in accessing the correct data. With patients iden-
tifying a reduction in pain as the most important treat-
ment attribute, question 1 of the SAT is designed to assess
this upfront. The patient interviews provided significant
insight into the impact that pain has on patients’ lives and
as a result questions 2 and 3 have been modified to reflect
the multiple areas on which pain has an impact. Daily ac-
tivities, physical activities, social activities and relation-
ships were identified by participants with varying types
and degrees of NP as facets of life that were affected by
pain. These aspects are also captured by Ko and colleagues
[39] who report that pain from PDPN interfered with ge-
neral activity, mood, walking, normal work, relationships,
sleep, and enjoyment of life. The addition of sleep and the
emotional impact of pain identified by the participants are
mirrored in the domain suggestions of the by the
IMMPACT group [7,19,40]. The suggested modifications
of the SAT enables patients to provide more details, as
uncovered in the patient interviews, about the way NP
affects their lives and the resulting impact of treatment in
areas of life that matter to NP patients. Additionally, the
consistency in pain and impact reports supports the con-
tent validity of the revised SAT, a critical component in
any self report instrument [34,41,42].
With the introduction of baseline and follow up ques-
tionnaires and the inclusion of onset and duration of action
of NP treatment, two important treatment attributes men-
tioned by patients in the interviews can be more efficiently
captured. The modifications to the SAT provide an instru-
ment that is more appropriate for use in clinical trials pro-
viding a baseline assessment and follow up assessments.
The previous recall bias is also amended and is more
in line with FDA recommendations than the previous
version as a result of the shorter recall period. The ques-
tions on the revised SAT are phrased in a consistent
fashion to facilitate the respondents’ answering. Both the
questions and the response options follow a similar pat-
tern as well as the inclusion of examples derived from
the interviews.
The content validity of the revised SAT has been sup-
ported by extensive qualitative research among diverse
NP populations and clinicians and NP treatment benefits
are now reflected in a more accurate and informed man-
ner in the measure. Further alterations may be necessary
once data on the measure performance has been col-
lected but currently the most fundamental concept that
of content validity has been assured. Without validity, a
measure with good psychometric properties but not
based on something real is not valid and has no use.
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